Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437944 | 0.95 | KMT2A (0.47) | MEN1KMT2ARAB9AOPRK1HPGD | |
| SCHEMBL12437728 | 0.89 | APP (0.48) | MEN1KMT2ATMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL12437721 | 0.88 | MEN1 (0.45) | MEN1KMT2ARAB9AOPRK1ALDH1A1 | |
| SCHEMBL12437719 | 0.88 | MEN1 (0.48) | MEN1KMT2ARAB9AOPRK1UTS2R | |
| SCHEMBL12437718 | 0.87 | MEN1 (0.46) | MEN1KMT2AOPRK1UTS2REPHX2 | |
| SCHEMBL12437957 | 0.87 | SLC5A7 (0.51) | MEN1KMT2AOPRK1ALDH1A1OPRM1 | |
| SCHEMBL12437336 | 0.86 | SLC5A7 (0.50) | MEN1KMT2AOPRK1ALDH1A1OPRM1 | |
| SCHEMBL12437962 | 0.86 | OPRK1 (0.45) | OPRK1UTS2REPHX2 | |
| SCHEMBL12437575 | 0.86 | OPRM1 (0.58) | MEN1KMT2ARAB9AHPGDALDH1A1 | |
| SCHEMBL12437734 | 0.85 | HRH1 (0.46) | MEN1KMT2ARAB9AOPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | MEN1 3974/4885KMT2A 2446/4885RAB9A 3232/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | MEN1 3974/4885KMT2A 2446/4885RAB9A 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.